�ٺ���Ƶ

Our Leadership

• 
  Faith E. Davies, MD
  

  Director, Center for Blood Cancers | Hematology

  Dr. Faith E. Davies is director of the Center for Blood Cancers at �ٺ���Ƶ’s Perlmutter Cancer Center. She leads a team of hematologist–oncologists, pathologists, and scientists across our locations with the goal of helping the center become a global leader in the investigation and treatment of blood cancers. Dr. Davies also fosters collaboration between scientists and clinicians, ensuring that our research and our clinical practice inform each other.

  Additionally, she serves as director of the Clinical Myeloma Program and is a professor in the Department of Medicine at NYU Grossman School of Medicine. She has published more than 350 research papers and is a member of the American Association for Cancer Research and the American Society of Hematology. Dr. Davies is researching new drugs and new drug combinations for the treatment of myeloma.

  View Full Profile
• 
  Catherine S. Diefenbach, MD
  

  Hematology

  Dr. Catherine S. Diefenbach is a lymphoma translational researcher who is director of hematology translational research and director of the Clinical Lymphoma Program. Dr. Diefenbach pioneered the use of immunotherapy in Hodgkin lymphoma. She serves as principal investigator for many lymphoma clinical trials, for therapies that include targeted therapy, immunotherapy, and radiation therapy, as well as a national clinical trial for patients with relapsed Hodgkin lymphoma. Her translational work concentrates on investigating the microbiome and how it relates to lymphoma immunity, and on novel CAR T strategies for patients with relapsed B cell lymphoma.

  View Full Profile
• 
  Christopher Y. Park, MD, PhD
  

  Hematopathology

  Dr. Christopher Y. Park is a clinical and research pathologist whose research focuses on blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). His laboratory works to identify genes that regulate AML or MDS stem cell self-renewal, differentiation, and therapy resistance, with the goal of developing better ways to diagnose, monitor, and treat patients. His group is actively pursuing the development of therapeutic antibodies to treat these disorders and is also investigating the use of artificial intelligence to evaluate digital pathology images to improve diagnostic sensitivity and accuracy.

  View Full Profile
• 
  Gareth J. Morgan, MD, PhD
  

  Hematology

  Dr. Gareth J. Morgan, director of multiple myeloma research, focuses on disease prevention strategies and treating patients with high-risk multiple myeloma and relapsed disease. Dr. Morgan also treats pre-myeloma conditions and conducts research on the precursors of the disease, with the aim of early diagnosis and prevention of more-advanced-stage myeloma. He has pioneered many studies on the genetics and treatment of multiple myeloma.

  View Full Profile
• 
  Iannis Aifantis, PhD
  

  Dr. Iannis Aifantis is the Hermann M. Biggs Professor of Pathology and chair of the Department of Pathology. His laboratory focuses on the molecular mechanisms of lymphoid and myeloid leukemia initiation and progression, using genomic and genetic approaches. Other areas of research focus include the impact of DNA methylation in stem cell transformation, mapping of long non-coding RNAs in human tumors, the impact of the 3D chromosomal architecture in cancer, and the role of stress responses in cancer malignancy.

• 
  Marc J. Braunstein, MD, PhD
  

  Hematology

  Dr. Marc J. Braunstein is program director of the Hematology and Medical Oncology Fellowship and course co-director of the Hematology Organ System at NYU Long Island School of Medicine. He treats patients with various types of hematologic conditions and specializes in plasma cell disorders, particularly multiple myeloma. He also performs stem cell transplants for some of these conditions. Dr. Braunstein is involved in research involving novel immunotherapy combinations for multiple myeloma and non-Hodgkin lymphoma, and is active in enrolling patient in clinical trials on Long Island.

  View Full Profile
• 
  Michael L. Grossbard, MD
  

  Hematology

  Dr. Michael L. Grossbard is the section chief in Hematology at Perlmutter Cancer Center and the chief of Hematology and Medical Oncology Inpatient Services at Tisch Hospital. Dr. Grossbard treats people with blood cancers, specializing in those with lymphoma and chronic lymphocytic leukemia (CLL), and he works to enhance clinical services and clinical trials for people who have blood or bone marrow conditions. Dr. Grossbard has developed novel antibody therapies for lymphoma that have now become the standard of care, and he participates in research trials to develop new treatments for blood cancers. He has been listed in Castle Connolly’s “Top Doctors” series for the New York metro area and America’s Top Doctors for more than 20 years.

  View Full Profile
• 
  Mohammad Maher Abdul Hay, MD
  

  Hematology, Bone Marrow Transplant

  Dr. Mohammad Maher Abdul Hay, associate professor of medicine at �ٺ���Ƶ, is the director of the Clinical Leukemia Program. He is also the medical unit director of the hematology–oncology and blood and marrow transplant service. Dr. Abdul Hay treats people with leukemia, myelodysplastic syndrome (MDS), and myeloproliferative disease (MPD), and is also a member of the blood and bone marrow transplant team. He provides CAR T cell therapies and autologous and allogeneic stem cell transplant services for patients. His research focuses on creating more effective targeted therapies for people with acute leukemias and myeloid malignancies by conducting early-phase clinical trials.

  View Full Profile
• 
  William L. Carroll, MD
  

  Pediatric Hematology-Oncology

  Dr. William L. Carroll is the Julie and Edward J. Minskoff Professor of Pediatrics and associate chair for clinical and translational research in the Department of Pediatrics, and is also a professor in the Department of Pathology. Dr. Carroll treats children who have blood cancers such as leukemia and lymphoma. He also conducts research focused on discovering the molecular origins of childhood cancers, with the goal of developing improved treatment and preventive measures.

  View Full Profile